Mangalam Drugs & Organics Clarifies No Material Information Behind Recent Price Movement

Mangalam Drugs & Organics Limited has issued a clarification to BSE Limited regarding recent price movements in its stock, confirming that no undisclosed material information is influencing the security's trading behavior. The pharmaceutical company's response, dated January 7, 2026, addresses BSE surveillance queries about unusual price activity.

Company's Position on Price Movement

The company has taken a clear stance on the recent price fluctuations, emphasizing that it bears no responsibility for market-driven price changes. According to the official communication, Mangalam Drugs & Organics believes that price movements are purely driven by market sentiment and investor behavior rather than any company-specific developments.

Parameter	Details
Reference Number	MDOL/CS-SE/2025-26/045
BSE Script Code	532637
Response Date	January 7, 2026
Signatory	Govardhan M. Dhoot, Managing Director
DIN	01240086

Regulatory Compliance Statement

The company has assured stakeholders of its commitment to regulatory compliance and transparency. In its response to BSE surveillance, Mangalam Drugs & Organics confirmed that it has been disclosing material information wherever applicable and in a timely manner. The management stated that to the best of their knowledge and belief, there is currently no material information or announcement pending dissemination that could impact the stock's price behavior.

Market Sentiment Attribution

Rather than attributing price movements to specific corporate developments, the company has pointed to broader market dynamics as the primary driver. The management emphasized that it would not be feasible for the company to respond to every price movement, given that such fluctuations are typically influenced by investor sentiment and market conditions beyond the company's direct control.

The clarification serves to address regulatory concerns while maintaining transparency with investors about the company's current operational status and disclosure practices.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.99%	+33.91%	+43.63%	-58.02%	-67.82%	-73.44%

Mangalam Drugs & Organics Limited has announced a key leadership change with the resignation of its Chief Financial Officer, effective March 31, 2025. The pharmaceutical company disclosed this development following a Board of Directors meeting held on March 29, 2025.

CFO Resignation Details

The Board of Directors approved the resignation of Mr. Ajay Samant from his position as Chief Financial Officer of the company. The resignation becomes effective from March 31, 2025, marking the end of his tenure with the organization.

Parameter:	Details
CFO Name:	Mr. Ajay Samant
Resignation Date:	March 28, 2025
Effective Date:	March 31, 2025
Board Approval:	March 29, 2025
Reason:	Attainment of retirement age

Reason for Resignation

The company clarified that Mr. Samant's resignation is due to the attainment of retirement age as per office guidelines. The CFO tendered his resignation on March 28, 2025, which was subsequently presented to the Board of Directors for approval during their meeting on March 29, 2025.

Regulatory Compliance

Mangalam Drugs & Organics acknowledged that it had inadvertently missed mentioning the reason for the CFO's resignation in its initial disclosure. The company has now provided complete information to ensure compliance with regulatory requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The disclosure was made to BSE Limited, where the company's shares are listed under scrip code 532637. The company requested the stock exchange to take note of this information and update their records accordingly.